A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment

BACKGROUND: Because the recurrence rate of hepatocellular carcinoma (HCC) is high, even after curative treatments such as hepatic resection and microwave ablation, chemopreventive agents that can effectively suppress HCC recurrence are required. Cyclooxygenase-2 (Cox-2) was recently found to be over...

Descripción completa

Detalles Bibliográficos
Autores principales: Takami, Yuko, Eguchi, Susumu, Tateishi, Masaki, Ryu, Tomoki, Mikagi, Kazuhiro, Wada, Yoshiyuki, Saitsu, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003903/
https://www.ncbi.nlm.nih.gov/pubmed/26846471
http://dx.doi.org/10.1007/s12072-016-9704-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003903/
https://www.ncbi.nlm.nih.gov/pubmed/26846471
http://dx.doi.org/10.1007/s12072-016-9704-y

Ejemplares similares